Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey

Actively recruiting top talent to support US market penetration -

READING, England and BEDMINSTER, New Jersey, August 23, 2010 - Archimedes Pharma, an emerging specialty pharma company focused on
oncology, pain, neurology and critical care sectors, announced today the
location of its new US headquarters in Bedminster, New Jersey.

Archimedes has offices in a number of European countries and markets a
range of therapeutics in Europe. The opening of its US office marks the
continued expansion of the company's global commercial presence. The New
Jersey location will provide Archimedes access to the deep resource pool of
New Jersey-based specialty pharma professionals. Archimedes will add a
significant number of positions this year, including sales & marketing,
regulatory, finance, human resources and medical affairs.

The New Jersey Economic Development Authority awarded a Business
Employment Incentive Program (BEIP) grant for Archimedes Pharma US to create
up to 75 new jobs. BEIP grants are available to businesses looking to expand
or relocate while creating job growth in New Jersey.

Jeffrey H. Buchalter, President and CEO of Archimedes Pharma, reaffirmed
Archimedes' commitment to New Jersey and said, "The new US headquarters in
Bedminster is a significant milestone in Archimedes' development as an
emerging global specialty pharmaceutical company. With Archimedes' rapidly
growing and diverse drug delivery technologies and products portfolio, we are
in the process of establishing our own US organization and are actively
recruiting top-tier senior-level management positions to support market
penetration across the USA and globally. The BEIP grant awarded to us by the
state was the deciding factor when choosing a US location. We're committed to
New Jersey and growth of the pharmaceutical business here."

Archimedes' lead product, PecFent(R), an innovative fentanyl nasal spray
for the treatment of breakthrough cancer pain, received a Positive Opinion
from the Committee for Human Medicinal Products (CHMP) of the European
Medicines Agency (EMA) in June 2010. A New Drug Application (NDA) for the
drug was submitted to the US Food and Drug Administration (FDA) in August
2009; discussions with the FDA are ongoing.

About Archimedes Pharma

Archimedes Pharma is a specialty pharmaceutical company marketing and
selling an expanding portfolio of specialist products to hospital-based
prescribers in major European territories.

Focused on the oncology, pain, neurology and critical care sectors,
Archimedes currently markets multiple therapeutics in the UK, France, Germany
and Ireland. The company is expanding its commercial presence in Spain and
the US.

Products currently marketed in Europe by Archimedes include: Gliadel, a
biodegradable wafer impregnated with carmustine for high-grade glioma;
Zomorph, an oral sustained release morphine product for moderate to severe
pain, particularly cancer pain; Oramorph, a liquid immediate release morphine
product also indicated for moderate to severe pain; Apomorphine Injection for
motor fluctuations in advanced Parkinson's disease; and Pabrinex, a high
potency vitamin formulation used to treat the symptoms of malnutrition
especially in patients with alcohol misuse problems.

Archimedes is also developing a robust, high-value pipeline of in-house
pain therapeutics, Parkinson's disease and critical care. It applies its
world-class drug delivery technologies to proven molecules that have yet to
achieve their market potential due to their current mode of delivery. This
approach reduces the company's development risk, while delivering significant
clinical and commercial benefits.

PecFent(R)

Archimedes' lead product is PecFent, an innovative and highly
differentiated fentanyl citrate nasal spray, which has been granted a
Positive Opinion by the CHMP for the treatment of breakthrough cancer pain.

PecFent is an aqueous fentanyl citrate solution utilizing Archimedes'
proprietary PecSys(TM) technology. The PecFent solution has a low viscosity
and is easily delivered in a low volume of 100mcl using a nasal spray pump.
The pump produces a fine mist of similarly sized spray droplets that are
deposited into the front of the nostril. The calcium ions present on the
nasal mucosa cause the pectin to form a thin gel layer, which allows fentanyl
to be retained on the nasal mucosa, allowing a rapid but controlled
absorption into the systemic circulation. The PecSys(TM) technology avoids
problems associated with simple solutions used in nasal sprays, such as
dripping or swallowing of the drug solution.

Archimedes' technologies - ChiSys(R), PecSys(TM) and TARGIT(R) - are also
used in a number of partnered products in late-stage clinical development.
ChiSys, an innovative drug delivery technology that enhances the residence
time of molecules on mucosal membranes, has proven potential for vaccine
delivery. Pre-clinical and clinical studies of nasally administered vaccines
have demonstrated enhanced immune response. PecSys(TM) is Archimedes'
patented drug delivery system built around its novel pectin technology,
designed to maximize the potential of systemically absorbed drugs by
enhancing drug performance and improving patient acceptance.

About Breakthrough Cancer Pain (BTCP)

Breakthrough cancer pain affects up to 95% of all cancer patients with
pain and is characterized by sudden, unpredictable episodes of intense pain
that occur despite background pain medication. This pain is rapid in onset,
usually reaching maximum intensity in five minutes and lasting for 30 to 60
minutes.

For more information, please visit: www.archimedespharma.com.

    Media contacts:
    Tiberend Strategic Advisors, Inc. (USA)
    Tamara Bright/Andrew Mielach, +1-212-827-0020
    tbright@tiberendstrategicadvisors.com /
    amielach@tiberendstrategicadvisors.com

    Citigate Dewe Rogerson (UK and Europe)
    Chris Gardner/Amber Bielecka, +44-207-638-9571
    chris.gardner@citigatedr.co.uk /
    amber.bielecka@citigatedr.co.uk

Tamara Bright, tbright at tiberendstrategicadvisors.com, or Andrew Mielach, amielach at tiberendstrategicadvisors.com, +1-212-827-0020, both of Tiberend Strategic Advisors, Inc. (USA); Chris Gardner, chris.gardner at citigatedr.co.uk, or Amber Bielecka, amber.bielecka at citigatedr.co.uk, +44-207-638-9571, both of Citigate Dewe Rogerson (UK and Europe)